Thursday, November 21, 2024
11/21/2024
PROJECT SUMMARY A frequent mode of therapy resistance is through the restoration of homologous recombination (HR) DNA repair, which can occur via secondary reversion mutations, or loss of DNA end resection proteins. While reversion events are commonly detected, mutations in DNA end resection proteins are less frequently reported in patients, and the molecular drivers of clinical resistance in many BRCA1 cancers remain unknown. In this proposal, we have identified genes that when mutated do not impact resection, but restore PALB2 recruitment and induce PARPi resistance. We now hypothesize that PARPi resistance can occur when mutations occur in genes that function to block PALB2 recruitment to sites of DNA damage. However, mechanistic details remain to be defined. The rationale for the proposed research is that PALB2 inhibitory proteins play a role in regulating mammalian DNA repair, and loss of function events may account for a significant portion of PARPi resistant patient cancers where RAD51 activity is restored, but mutations in DNA end resection genes or BRCA1 reversion mutations are not detected. We will validate these resistance pathways in relevant mouse models of BRCA1 mutant cancer. We will address the following Specific Aims: 1) define molecular features of PALB2 required for HR.; 2) elucidate mechanisms of PALB2 inhibition; and 3) examine the role of PALB2 regulators in PARPi resistance. Collectively, these studies have the potential to reveal new paradigms for DNA repair pathway choice and therapy response and resistance.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
